Atreca (Atreca) Operating Cash Flow per Share : $-1.66 (TTM As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Atreca Operating Cash Flow per Share?

Atreca's operating cash flow per share for the three months ended in Sep. 2023 was $-0.44. Atreca's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.66.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 17.30% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 34.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Atreca's Operating Cash Flow per Share or its related term are showing as below:

BCEL' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 17.3 Med: 43.1 Max: 46.5
Current: 17.3

During the past 6 years, Atreca's highest 3-Year average Operating Cash Flow per Share Growth Rate was 46.50% per year. The lowest was 17.30% per year. And the median was 43.10% per year.

BCEL's 3-Year OCF Growth Rate is ranked better than
65.03% of 1241 companies
in the Biotechnology industry
Industry Median: 3.7 vs BCEL: 17.30

Atreca Operating Cash Flow per Share Historical Data

The historical data trend for Atreca's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atreca Operating Cash Flow per Share Chart

Atreca Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Cash Flow per Share

Get a 7-Day Free Trial

-10.75

-3.70

-2.09

-1.65

-2.09

Atreca Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.42	-0.40	-0.37	-0.46	-0.44

Competitive Comparison of Atreca's Operating Cash Flow per Share

For the Biotechnology subindustry, Atreca's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atreca's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atreca's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Atreca's Price-to-Operating-Cash-Flow falls into.

Atreca Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Atreca's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (A: Dec. 2022 )	=	Cash Flow from Operations (A: Dec. 2022 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2022 )
	=	-80.721	/	38.594
	=	-2.09

Atreca's Operating Cash Flow per Share for the quarter that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (Q: Sep. 2023 )	=	Cash Flow from Operations (Q: Sep. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2023 )
	=	-17.216	/	39.355
	=	-0.44

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.66

Atreca Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Atreca's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Atreca (Atreca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atreca Inc (OTCPK:BCEL) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

0C1:Germany

Address

835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.atreca.com

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Executives

Felix Baker	other: Former 10% Owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	other: Former 10% Owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	other: Former 10% Owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	other: Former 10% Owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Roger Richard Ruiz	officer: VP of Finance	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Stephen E Gould	officer: Chief Scientific Officer	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Tito Serafini	director, officer: Chief Strategy Officer	C/O ATRECA, INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Phillips Courtney	officer: General Counsel & Secretary	ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Philippe C Bishop	officer: Chief Medical Officer	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
John A Orwin	director, officer: President & CEO	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Stacey Ma	director	C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS CA 94070
Stephen R Brady	director	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Norman Michael Greenberg	officer: Chief Scientific Officer	500 SAGINAW DRIVE, REDWOOD CITY CA 94063
William Hewitt Robinson	director	500 SAGINAW DRIVE, REDWOOD CITY CA 94063